Blood Advances in a Different Vein

Blood Advances in a Different Vein

Research from recent issues of Blood Advances

Managing Toxicities of Dasatinib in Patients With CP-CML

In randomized studies, the second-generation tyrosine kinase inhibitor dasatinib demonstrated deeper and more rapid major molecular responses (MRs) in patients with newly diagnosed chronic-phase...

Are HCT Patients in Brazil at Increased Risk of Zika and Other Mosquito-Transmitted Infections?

Since 2015, Brazil has experienced a triple epidemic of dengue, chikungunya, and Zika infections, putting the more than 2,000 hematopoietic cell transplantation (HCT) recipients...

Long-Term Study Highlights Limitations of Current TTP Diagnostic Methods

For the past two decades, ADAMTS13 activity has been the backbone of diagnosis for thrombotic thrombocytopenic purpura (TTP); however, a long-term registry study published...

Investigating Trends in Survival Outcomes Among the Oldest Patients with DLBCL

The probability of developing non-Hodgkin lymphoma (NHL) increases with age. Thus, as the U.S. population ages, a greater number of patients are at risk...

Examining Hemoglobin Variants and Geographic Variability of Sickle Cell Trait and Sickle Cell Disease...

Results from the prospective Uganda Sickle Surveillance Study (US3), which was created through a partnership among the Uganda Ministry of Health, Makerere University, and...

Newly Identified DNA Mutations Predict for Worse Survival Among Patients With Polycythemia Vera and...

The driver mutations JAK2, CALR, and MPL have prognostic and diagnostic significance for patients with the myeloproliferative neoplasms polycythemia vera (PV) and essential thrombocythemia...
Advertisement

Current Issue

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.